GlassScriptPhysician profile
Kumar S Gandhi
NPI 1821369877
$2,260.77
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $18.37 · 2021: $222 · 2022: $232 · 2023: $1,312 · 2024: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,646.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $594.82 | 2022-2024 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $471.78 | 2021-2024 | Lybalvi, Aristada, Aristada Initio |
| Glaxosmithkline, LLC. | $391.40 | 2021-2024 | Bexsero, Arexvy, Rotarix |
| Novo Nordisk INC | $148.68 | 2023 | Wegovy, Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $100.52 | 2023-2024 | Uzedy, Austedo Xr, Austedo |
| Merck Sharp & Dohme LLC | $85.60 | 2019-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.72 | 2023-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $58.23 | 2023-2024 | Hetlioz, Fanapt |
| Sanofi-Aventis U.S. LLC | $48.46 | 2019 | |
| Lilly USA, LLC | $43.75 | 2023 | Mounjaro |
| Neurocrine Biosciences, INC. | $32.09 | 2022 | |
| Axsome Therapeutics, INC. | $31.82 | 2023 | Auvelity |
| Evofem Biosciences, INC. | $31.64 | 2021-2022 | |
| Therapeuticsmd, INC. | $28.78 | 2019 | |
| Roche Diagnostics Corporation | $21.88 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $21.11 | 2019 | |
| Eisai INC. | $19.52 | 2021 | |
| Noven Therapeutics, LLC | $19.36 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.34 | 2019 | |
| Circassia INC. | $14.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Gandhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.